AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. SEC-Filings
  3. EPRX

Eupraxia Pharmac SEC Filings

EPRX NASDAQ

Welcome to our dedicated page for Eupraxia Pharmac SEC filings (Ticker: EPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Parsing Eupraxia Pharmaceuticals� disclosures isn’t just time-consuming—it requires a working knowledge of DiffuSphere science, cash-burn dynamics, and FDA milestones. Our platform tackles that complexity head-on. Stock Titan’s AI reads every page of each Eupraxia Pharmaceuticals annual report 10-K, quarterly earnings report 10-Q filing, and 8-K material event so you don’t have to.

Need the phase readout date hidden in a footnote? Want rapid alerts on Eupraxia Pharmaceuticals insider trading Form 4 transactions? Our real-time feed captures Form 4 insider transactions the moment they post to EDGAR and delivers plain-English summaries. You’ll also see side-by-side comparisons of R&D spend, cash runway, and trial costs—key data points biotech investors track before dilution risks emerge.

Whether you’re seeking Eupraxia Pharmaceuticals proxy statement executive compensation details, a DiffuSphere patent update inside an 8-K, or simply understanding Eupraxia Pharmaceuticals SEC documents with AI, everything lives here. Each filing is paired with an AI-powered summary, contextual tags (SPRINGBOARD, RESOLVE), and quick links to deeper earnings report filing analysis. Monitor executive stock transactions Form 4, explore Eupraxia Pharmaceuticals annual report 10-K simplified sections, and follow every Eupraxia Pharmaceuticals quarterly earnings report 10-Q filing—updated in real time and explained simply.

Filing

[6-K] Eupraxia Pharmaceuticals Inc. Current Report (Foreign Issuer)

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
current report
-
Filing

[6-K] Eupraxia Pharmaceuticals Inc. Current Report (Foreign Issuer)

Rhea-AI Summary
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.51%
Tags
current report

FAQ

What is the current stock price of Eupraxia Pharmac (EPRX)?

The current stock price of Eupraxia Pharmac (EPRX) is $5.06 as of July 23, 2025.

What is the market cap of Eupraxia Pharmac (EPRX)?

The market cap of Eupraxia Pharmac (EPRX) is approximately 193.0M.

What is Eupraxia Pharmaceuticals focused on?

Eupraxia is focused on developing locally delivered, extended-release therapies for conditions with significant unmet medical needs, including osteoarthritis and eosinophilic esophagitis.

What technology underpins Eupraxia's approach?

The Company utilizes its proprietary DiffuSphere technology, a polymer-based microsphere system that ensures targeted, stable, and tunable drug release to maximize local efficacy and minimize systemic side effects.

Which clinical programs are currently underway?

Eupraxia is advancing two key clinical programs: the RESOLVE trial for EP-104GI in eosinophilic esophagitis and the SPRINGBOARD trial for EP-104IAR in knee osteoarthritis.

How does DiffuSphere technology differ from conventional drug delivery?

Unlike standard delivery methods that show steep peaks and rapid declines, DiffuSphere provides a stable, flat drug release profile that maintains therapeutic levels locally while reducing systemic exposure and related adverse events.

What advantages does localized drug delivery offer?

Localized delivery targets the affected tissue directly, improving the drug's efficacy, reducing side effects, and allowing for a prolonged duration of action, which can enhance patient outcomes.

How does Eupraxia enhance its expertise and reliability?

Eupraxia combines extensive preclinical research, advanced clinical trial designs, and cross-disciplinary expertise to ensure rigorous scientific evaluation and adherence to regulatory standards, reinforcing its credibility in the biotech industry.

What types of therapeutic conditions could benefit from this technology?

Beyond osteoarthritis and eosinophilic esophagitis, Eupraxia’s platform has potential applications in other inflammatory conditions and possibly oncology, where precise, localized drug delivery is advantageous.

Does the company provide direct investment advice?

No, the information provided is for informational purposes only and reflects a neutral, analytical view of Eupraxia’s business model and clinical progress without offering investment advice.
Stock EPRX logo
Eupraxia Pharmac

NASDAQ:EPRX

EPRX Rankings

#6138 Ranked by Market Cap
N/A Ranked by Dividends

EPRX Stock Data

192.96M
28.97M
22.56%
13.09%
0.44%
Biotechnology
Healthcare
Canada
Victoria